ClinicalTrials.gg
RecruitingNCT06239311Updated Aug 27, 2025

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

A Phase 3 interventional study of Methotrexate and Placebo in Moderate to Severe Atopic Dermatitis, sponsored by medac GmbH. Recruiting at 30 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by medac GmbH · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 159 studies in Dermatitis, Atopic with a site in Poland — 12 open to participants now, 32 under way, 10 of them phase 3. Dermatitis, Atopic · Poland.

Planned enrollment
69th of 151
277 · median 250
Started
2024
with 13 others
Phase 3
60 of 159
4 open now
Primary completion
2026-11
later than 10 of 31 live
Registered
121st of 159
by date

Among the 159 studies in Dermatitis, Atopic with a site in Poland, this one is the 69th largest by planned enrollment of the 151 interventional ones that give a count, is one of 14 that started in 2024, is one of 60 in phase 3, reaches primary completion later than 10 of the 31 other live ones, and was the 121st registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

12 of the 159 studies in Dermatitis, Atopic with a site in Poland are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies in Dermatitis, Atopic with a site in Poland, or all of them as a file.
02

Study summary

Atopic dermatitis is an ongoing condition that causes skin irritation, redness, and itchiness. Treatments are usually topical - applied to the skin (e.g., moisturisers or medicated creams) - but a wider variety of systemic treatments (that target the whole body) are needed for those whose condition does not improve with topical treatments. Methotrexate, a drug approved for similar conditions such as arthritis and psoriasis, has been shown to improve atopic dermatitis. This randomised, controlled clinical trial will investigate how effective.

03

Conditions studied

  • Moderate to Severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman of must have a negative pregnancy test at the Screening Visit and must agree to use highly effective methods of while taking the medicinal product (IMP) and for 6 months after the last IMP administration. Men must agree to use a condom during intercourse while taking the IMP and for 3 months after the last IMP administration. They must also agree to not donate sperm for the time period starting at the Screening Visit, throughout the entire trial period, and for at least 3 months after the last IMP administration.
  • Diagnosis of atopic dermatitis (AD) at least 12 months prior to the Screening Visit, diagnosed as defined by the Hanifin and Rajka criteria for AD 4.
  • Moderate to severe AD, defined as the following criteria at the Baseline Visit: Eczema Area and Severity Index (EASI) ≥ 16, Investigator Global Assessment (IGA) ≥ 3, Dermatology Life Quality Index (DLQI) ≥ 10
  • Eligible for systemic treatment, ie, documented history (within 12 months prior to Baseline Visit) of inadequate response to treatment with topical (TCS) or topical calcineurin inhibitors (TCI)s or documented systemic treatment for AD (such as cyclosporine (CYC), azathioprine and/or mycophenolate mofetil). Inadequate response to TCS or TCI is defined as failure to obtain or maintain a remission or a low activity disease (IGA ≥ 2) despite a daily treatment with a class 2 or class 3 TCS or TCI for 28 days (or the maximal authorised duration according to the Summary of Product Characteristics (SmPC))
  • Treated with a stable dose of topical emollient, for at least 7 consecutive days prior to the Baseline Visit
  • Chest X-ray without abnormalities performed within the last 6 months prior to the Baseline Visit
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • Willing and able to comply with the protocol requirements for the duration of the trial
  • Covered by health care insurance in accordance with local requirements

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women, or planning to become pregnant, or to breastfeed during the trial
  • Previously treated with MTX
  • Presenting a known to MTX or folic acid as well as to any of the
  • Presenting ulcers of the oral cavity and known active gastrointestinal ulcer disease
  • Presenting with known blood dyscrasia ( \< 8.0 g/dL or white blood cell count \< 4000/mm3 or count \< 100000/mm3)
  • Presenting liver impairment and/or (AST) or alanine aminotransferase (ALT) > 2 times the (ULN), or > 5 mg/dL (85.5 μmol/L), or a positive result in the FibrotestTM at the Screening Visit
  • Presenting drug or alcohol abuse within the last 12 months
  • Presenting renal impairment ( less than 60 mL/min)
  • Presenting serious, acute or chronic infections such as tuberculosis, or C, positive, or other immunodeficiency syndromes

    1. A positive test result at Screening for hepatitis B surface antigen (HBsAg) and/or core antibodies (anti-HBc) excludes the patient from trial participation. Patients with positive surface antibodies (anti-HBs) and a history of hepatitis B virus (HBV) vaccination may be included.
    2. A positive test result at Screening for (positive hepatitis C virus (HCV) antibody test confirmed with positive hepatitis C RNA test) excludes the patient from trial participation, even if they have received appropriate and effective treatment, due to the risk of reactivation.
    3. If the interferon-gamma release assay shows a positive result at the Screening Visit the patient may only be included in the trial if the tuberculosis is latent and all of the following 3 conditions are true: (i) Chest X-ray does not show evidence suggestive of active tuberculosis. (ii) There are no clinical signs and symptoms of pulmonary and/or extra-pulmonary tuberculosis. (iii) Documented receipt of one of the following prophylactic treatment regimens: Oral daily isoniazid for 6 months or Oral daily rifampin for 4 months or Isoniazid and rifapentine weekly for 3 months. The IMP can only be administered to a participant with a positive test result in the interferon-gamma release assay (or an indeterminate result if only 1 test is done, or 2 indeterminate results if a second test is done after the first indeterminate test result) after the approval of a tuberculosis specialist.
  • Presenting uncontrolled infection, hospitalisation due to uncontrolled infection or treatment with intravenous antibiotics for infection within 2 months prior to the Baseline Visit
  • Presenting a history of , including solid tumours and haematologic malignancies, except non-melanoma skin cancer (epithelial cell carcinoma or basal cell carcinoma) and cervical carcinoma in situ that have been treated with no evidence of recurrence during the past 5 years
  • Currently experiencing or having a history of other concomitant skin conditions that would interfere with evaluation of AD (eg. psoriasis, lupus erythematosus, eczema herpeticum)
  • Treated with an drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before the Baseline
  • Treated with TCS, calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the Baseline Visit
  • Treated with oral , azathioprine, mycophenolate mofetil, CsA (Ciclosporin A) or any other systemic immunosuppressor / immunomodulator within 4 weeks before the Baseline Visit
  • Treated by specific allergen immunotherapy started within 3 months before the Baseline Visit 17
  • Treated with a monoclonal antibody (including but not limited to dupilumab or tralokinumab) within the last 3 months or 5 times the half-life of the respective monoclonal antibody (whichever is the longer period) or with any JAK (Janus kinase) inhibitors (including but not limited to ruxolitinib, baricitinib, tofacitinib, upadicitinib, or abrocitinib) within the last 4 weeks prior to the Baseline Visit
  • Treated with any parenteral corticosteroid within 6 weeks prior to the Baseline Visit
  • Treated with ultraviolet therapy within 4 weeks prior to the Baseline Visit
  • Received a live (attenuated) vaccine within 4 weeks before the Baseline Visit or planning to be vaccinated with during the trial. Please note: Since MTX may have an effect on the immune system, vaccination with live vaccines must not be performed during MTX administration
  • Having a planned surgery during the trial
  • Presenting a medical disease that is uncontrolled despite treatment that, in the opinion of the Investigator, is likely to impact the ability to participate in the trial or to impact the trial efficacy or safety assessments
  • Presenting any additional condition that, in the opinion of the Investigator, may interfere with the assessment or may put the participant at risk
  • Protected by the law (adult under guardianship, or hospitalised in a public or private institution for a reason other than this trial, or incarcerated)
  • Persons performing mandatory military service, persons deprived of liberty, persons who, due to a judicial decision, cannot take part in clinical trials, and persons, who due to their age, disability or state of health are reliant on care and for that reason accommodated in residential care institutions, that is accommodations providing an uninterrupted assistance for persons who necessitate such assistance, are in a situation of subordination or factual dependency and therefore may require specific protective measures
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
277 participants (estimated)

Study arms

  • Active comparator
    Methotrexate

    Participants will receive 16 to 24 weekly subcutaneous injections of 20 mg . In case of intolerance of the 20 mg dose, a reduction to 15 mg per week is possible.

    Drug: Methotrexate

  • Placebo comparator
    Placebo

    Participants will receive 16 to 24 weekly subcutaneous injections

    Drug: Placebo

Interventions

  • Solution for injection in prefilled pen

  • DrugPlacebo

    Solution for injection in prefilled pen

06

What researchers measure

Primary outcomes

  1. Eczema Area and Severity Index (EASI) 75 response at Trial Week 16 Visit

    To demonstrate the superiority of subcutaneous (SC) methotrexate (MTX) versus placebo with respect to an improvement from baseline of at least 75% of the Eczema Area and Severity Index (EASI 75 response). The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).

    Time frame: Trial Week 16

Secondary outcomes

  1. Improvement from baseline of at least 50% in the Eczema Area and Severity Index (EASI 50 response)

    The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  2. Improvement from baseline of at least 75% in the Eczema Area and Severity Index (EASI 75 response)

    The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in AD. The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 24

  3. Improvement from baseline of at least 90% in the Eczema Area and Severity Index (EASI 90 response)

    The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  4. Change from baseline in the Eczema Area and Severity Index (EASI) score.

    The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  5. Scoring Atopic Dermatitis (SCORAD) 50 response

    Response is defined as an improvement from baseline of at least 50%. The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  6. Scoring Atopic Dermatitis (SCORAD) 75 response

    Response is defined as an improvement from baseline of at least 75%. The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16,

  7. Change in Scoring Atopic Dermatitis (SCORAD) score from baseline

    The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  8. Investigator Global Assessment (IGA) response

    Investigator Global Assessment (IGA) response is defined as either an IGA score of 0 (clear) or 1 (almost clear) and a reduction of the score of at least 2 points. The IGA score is a 5-point scale with morphologic descriptors for each score to assess the severity of atopic dermatitis from 0 - Clear 4 - Severe.

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16, Trial Week 24

  9. Pruritus Numerical Rating Scale (NRS) response

    The Pruritus Numerical Rating Scale (NRS) response is defined as a decrease of the worst daily Pruritus NRS score from baseline by at least 4 points in participants with an NRS of at least 4 points at baseline. The NRS is a single item designed to capture information on self-reported severity of worst itching each day on an 11-point scale from 0 ("no itch") to 10 ("worst itch imaginable").

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16, Trial Week 24

  10. Change from baseline in Pruritus Numerical Rating Scale (NRS) score

    The Pruritus Numerical Rating Scale (NRS) is a single item designed to capture information on self-reported severity of worst itching each day on an 11-point scale from 0 (no itch) to 10 (worst itch imaginable).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  11. Patient-oriented Eczema Measure (POEM) response

    Patient-oriented Eczema Measure (POEM) response is defined as reduction from baseline of at least 4 points. The POEM is a seven-item, patient-reported questionnaire assessing atopic dermatitis (AD)/eczema-specific symptoms over the last week; each item is scored 0 (no days) to 4 (every day) based on the number of days affected. The minimum POEM score is 0 (best result) and the maximum total POEM score is 28 (worst result).

    Time frame: Trial Week 8, Trial Week 16

  12. Change from baseline in POEM score

    The POEM is a seven-item, patient-reported questionnaire assessing atopic dermatitis (AD)/eczema-specific symptoms over the last week; each item is scored 0 (no days) to 4 (every day) based on the number of days affected. The minimum POEM score is 0 (best result) and the maximum total POEM score is 28 (worst result).

    Time frame: Trial Week 8, Trial Week 16

  13. Adverse events (AE), treatment-related AEs, serious adverse events (SAEs) and serious adverse reactions (SARs)

    For participants who have not reached EASI 50 by the Trial Week 16 Visit and do not enter the extension phase: Adverse events (AE), treatment-related AEs, serious adverse events (SAEs) occurring from the Screening Visit until Trial Week 16 Visit, and serious adverse reactions (SARs) occurring from start of the trial intervention until the Trial Week 20 Visit For participants who do reach EASI 50 by the Trial Week 16 Visit and do enter the extension phase: AEs, treatment-related AEs, SAEs occurring from the Screening Visit until End of Extension Visit (Trial Week 24), and SARs occurring from start of the trial intervention until the Follow-up Visit (Trial Week 33)

    Time frame: Trial Week 16, Trial Week 20, Trial Week 24, Trial Week 33

  14. Dermatology Life Quality Index (DLQI) response

    Dermatology Life Quality Index (DLQI) response is defined as reduction of at least 4 points in DLQI from baseline. The DLQI is a 10-item questionnaire assessing health-related quality of life over the last week in patients with dermatological symptoms, with each item scored for impact from not at all (0) to very much (3).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  15. Change from baseline in Dermatology Life Quality Index (DLQI) score.

    The Dermatology Life Quality Index (DLQI) is a 10-item questionnaire assessing health-related quality of life over the last week in patients with dermatological symptoms, with each item scored for impact from not at all (0) to very much (3).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  16. Change from baseline in Scoring Atopic Dermatitis (SCORAD) sleep score

    Scoring Atopic Dermatitis (SCORAD) sleep score is a subset of the SCORAD related to the subjective symptoms section (insomnia) sleeplessness will be evaluated by the participant (based on the quality of life in the past 3 days). A 10 cm visual analogue scale is used, with 0 for no symptom and 10 for most severe symptom.

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  17. Change from baseline in Work Productivity and Activity Impairment: General Health (WPAI:GH)

    The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire consists of 6 questions assessing the effect of AD (including physical and emotional problems or symptoms) on the participant's ability to work and to perform regular activities. The questions are computed according to specific calculation rules and have four scores. High scores indicate prolonged sick leave or impairment and decreased productivity.

    Time frame: Trial Week 8, Trial Week 16

  18. Change from baseline in Hospital Anxiety and Depression (HADS) score and subscales

    Hospital Anxiety and Depression (HADS) is a fourteen-item scale with seven items each for anxiety and depression subscales. Each subscale can score between 0 (best result) and 21 (worst result) for either anxiety or depression.

    Time frame: Trial Week 8, Trial Week 16

  19. Change from baseline in European Quality of Life (EuroQoL) Group 5 Dimension 5 Levels (EQ-5D-5L)

    The European Quality of Life (EuroQoL) Group 5 Dimension 5 Levels (EQ-5D-5L) consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions, each dimension has 5 levels. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number ranging from 11111 (full health) to 55555 (worst health). The EQ VAS records the participant's self-rated health on a vertical visual analogue scale from 0 (The worst health you can imagine) to 100 (The best health you can imagine).

    Time frame: Trial Week 8, Trial Week 16

  20. Change from baseline in Atopic Dermatitis Control Tool (ADCT) score

    The Atopic Dermatitis Control Tool (ADCT) is a validated tool to evaluate the different dimensions of patient-perceived atopic dermatitis (AD) control. It consists of 6 questions, each scored from 0 to 4. The minimum total ADCT score is 0 (best result) and the maximum total ADCT score is 24 (worst result).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

  21. Eczema Area and Severity Index (EASI) 75 response at Trial Week 24 and the Follow-up Visit (Week 33)

    The Eczema Area and Severity Index (EASI) response in those participants who had an EASI 75 response at Trial Week 24 and did not need any systemic treatment for AD (relapse) until the Follow-up Visit. The EASI is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).

    Time frame: Trial Week 24, Trial Week 33

  22. Scoring Atopic Dermatitis (SCORAD) 90 response

    Response is defined as an improvement from baseline of at least 90%. The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).

    Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16

07

Study locations

20 of 30 sites recruiting
  • MU Dr. Petr Arenberger, DrSc. MBA
    Prague, Praha 1 11000, Czechia
    Recruiting
  • Synexus Czech s.r.o.
    Prague, Praha 2 12000, Czechia
    Terminated

    Not enrolling at this site — choose another above.

  • Praglandia s.r.o.
    Prague, Praha 5 15000, Czechia
    Recruiting
  • AGE Centrum s.r.o.
    Olomouc, 77900, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • CCR Ostrava s.r.o,
    Ostrava, 702 00, Czechia
    Recruiting
  • CCR Czech Pardubice a.s.
    Pardubice, 53000, Czechia
    Recruiting
  • Clintrial s.r.o.
    Prague, 10000, Czechia
    Recruiting
  • Dermatology clinic MUDr. Blanka Havlickova
    Prague, 11000, Czechia
    Recruiting
  • Centre Hospitalier Universitaire de Bordeaux - Hopital Saint Andre
    Bordeaux, 33075, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centre Hospitalier universitaire (CHU) de Clermont Ferrand Hopital d'Estaing
    Clermont-Ferrand, 63003, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Universitaire De Nantes
    Nantes, 44093, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, 69495, France
    Recruiting
  • Ospedale San Donato di Arezzo
    Arezzo, 52100, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria di Ferrara Arcispedale Sant' Anna
    Ferrara, 44124, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ospedale Piero Palagi
    Florence, 50125, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Universita degli Studi della Campania "Luigi Vanvitelli" - Azienda Ospedaliera Universitaria
    Naples, 80138, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero-Universitaria di Parma
    Parma, 43126, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Pisana (AOUP)
    Pisa, 56126, Italy
    Recruiting
  • Synexus Polska Sp. z o.o. in Czestochowa
    Częstochowa, 42-202, Poland
    Recruiting
  • Synexus Polska Sp. z o.o. Oddzial w Gdansku
    Gdansk, 80-382, Poland
    Recruiting
  • Synexus Polska Sp. z o.o. Oddzial w Katowicach
    Katowice, 40-040, Poland
    Recruiting
  • Angelius Badania Kliniczne
    Katowice, 40-611, Poland
    Recruiting
  • Synexus Polska Sp. z. o.o. Oddzial W Lodzi
    Lodz, 90-127, Poland
    Recruiting
  • LUXDERM Specjalistyczny Gabinet Dermatologiczny Prof. dr hab. n. med. Dorota Krasowska
    Lublin, 20-573, Poland
    Recruiting
  • Klinika Zdybski
    Lublin, 20-607, Poland
    Recruiting
  • Twoja Klinika
    Mikołów, 43-190, Poland
    Recruiting
  • Synexus Polska Sp z o.o. Oddzial W Poznaniu
    Poznan, 60-702, Poland
    Recruiting
  • Laser Clinic
    Szczecin, 70-332, Poland
    Recruiting
  • Synexus Polska Sp. Z o.o. Odział w Warszawie
    Warsaw, 02-672, Poland
    Recruiting
  • Klinika Ambroziak Dermatologia
    Warsaw, 02-953, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Nov 2026, 33 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 33 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Feb 2, 2024
StartActual
Feb 27, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Apr 2027
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06239311
Lead sponsor
medac GmbH
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Feb 27, 2024
Primary completion
Nov 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 27, 2025

Study contacts

Medac Clinical Trial Information
Contact
ClinicalTrialInformation@medac.de
+49 (0)4103 8006 ext. 0
Audrey Nosbaum, MD PhD
principal investigator · Université Lyon 1 / INSERM U1111 - CIRI / Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion